Skip to main content

Septerna, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

SEPN$50.74+3.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Septerna, Inc.
Date: March 9, 2026By:/s/ Jeffrey Finer, M.D., Ph.D.
Jeffrey Finer, M.D., Ph.D.
Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Jeffrey Finer and Gil M. Labrucherie, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following person in the capacities and on the date indicated.

NameTitleDate
/s/ Jeffrey Finer, M.D., Ph.D.Chief Executive Officer and DirectorMarch 9, 2026
Jeffrey Finer, M.D., Ph.D.(principal executive officer)
/s/ Gil M. Labrucherie, CFA, J.D.Chief Financial OfficerMarch 9, 2026
Gil M. Labrucherie, CFA, J.D.(principal financial officer and principal accounting officer)
/s/ Jeffrey Tong, Ph.D.Chairman and DirectorMarch 9, 2026
Jeffrey Tong, Ph.D.
/s/ Abraham Bassan, M.S.DirectorMarch 9, 2026
Abraham Bassan, M.S.
/s/ Bernard Coulie, M.D., Ph.D., M.B.A.DirectorMarch 9, 2026
Bernard Coulie, M.D., Ph.D., M.B.A.
/s/ Alan Ezekowitz, M.D., D.Phil.DirectorMarch 9, 2026
Alan Ezekowitz, M.D., D.Phil.
/s/ Shalini Sharp, M.B.A.DirectorMarch 9, 2026
Shalini Sharp, M.B.A.
/s/ Jake Simson, Ph.D.DirectorMarch 9, 2026
Jake Simson, Ph.D.
/s/ Keith Gottesdiener, M.D.DirectorMarch 9, 2026
Keith Gottesdiener, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.